Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

doi:10.4254/wjh.v6.i10.759

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 10

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9209)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

351

WORD

250

HTML

5726

Figures (1-3)

222

Tables (1-1)

224

Sum=6773

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1043

Download

1393

Sum=2436

Oct 27, 2014 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Hepatol. Oct 27, 2014; 6(10): 759-765
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.759

Full Size Figure Download Figure

Figure 1 Flow chart of systematic review of protease inhibitor based triple therapy.

Citation: Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765
URL: https://www.wjgnet.com/1948-5182/full/v6/i10/759.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i10.759